Abstract
Introduction/BackgroundThe treatment of patients with high risk endometrial cancer remains controversial, with PORTEC 3 reporting no significant overall survival benefit in patients receiving chemoradiotherapy compared with radiotherapy alone. In this...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have